Nephrolithiasis: A Comprehensive Review of Pathophysiology, Clinical Presentation, and Management
Journal of Innovations in Pharmaceutical and Biological Sciences · 2026 · 13 (01) · 83-95
DOI: 10.56511/jipbs.2026.13110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Innovations in Pharmaceutical and Biological Sciences, 2026. Verfasst von S. B Bothra und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Nephrolithiasis affects approximately 12% of the global population with increasing prevalence linked to obesity, metabolic syndrome, and dietary factors. Calcium oxalate and calcium phosphate stones comprise 70–80% of cases, followed by uric acid (10–15%), struvite (10–15%), and cystine stones (
Zitieren
APA
Bothra, S. B., Baig, S. S., & Yahya, B. A. (2026). Nephrolithiasis: A Comprehensive Review of Pathophysiology, Clinical Presentation, and Management. Journal of Innovations in Pharmaceutical and Biological Sciences, 13(01), 83-95. https://doi.org/10.56511/jipbs.2026.13110
Vancouver
Bothra SB, Baig SS, Yahya BA. Nephrolithiasis: A Comprehensive Review of Pathophysiology, Clinical Presentation, and Management. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):83-95. doi:10.56511/jipbs.2026.13110
BibTeX
@article{Bothra2026,
author = {Bothra, S. B and Baig, Shahajan Shabbir and Yahya, Barrawaz Aateka},
title = {Nephrolithiasis: A Comprehensive Review of Pathophysiology, Clinical Presentation, and Management},
journal = {Journal of Innovations in Pharmaceutical and Biological Sciences},
year = {2026},
volume = {13},
number = {01},
pages = {83--95},
doi = {10.56511/jipbs.2026.13110}
}
EUVIMED